Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective foscarbidopa/ foslevodopa is in treating German adult participants at initial stages of advanced Parkinson's disease under routine clinical practice.
Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 125 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 20 sites in Germany.
Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 12 months.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Participants with a diagnosis of levodopa-responsive idiopathic Parkinson's disease
Eligibility for foscarbidopa/foslevodopa (LDp/CDp) therapy in accordance with the approved local label
Participant must be an adult male or female, 18-67 years of age
Time since beginning of motor fluctuations <= 5 years
Previous Exposure to any device-aided therapy (DAT).
Any condition included in the contraindications section of the approved local LDp/CDp label.
Participants with Mini mental state examination (MMSE) score < 24
Participants with advanced Parkinson's disease with time since the beginning of motor fluctuations \<= 5 years and the Hoehn and Yahr (H\&Y) stage \<= 3 in the on-medication condition treated with foslevodopa/foscarbidopa according to label in Germany
Cohort
Prospective
Not listed
Change From Baseline in OFF Time (hours)
The mean change from baseline to each scheduled visit in the number of hours spent in OFF time will be estimated using a mixed-effect model repeated-measures (MMRM).
